Destiny Pharma has joined other pharmaceutical companies. including GlaxoSmithKline, Merck , Pfizer, Sanofi, Novartis and AstraZeneca, in calling on governments to work with them to develop new and alternative market structures that provide more dependable and sustainable market models for antibiotics, and to commit the funds needed to implement them. The Declaration, by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance was launched at the World Economic Forum in Davos, Switzerland last week. The Declaration was drafted, agreed and signed by 85 companies and nine industry associations from across the global pharmaceutical, diagnostics and biotechnology industries in 18 different countries. The statement sets out for the first time how governments and industry need to work together to support sustained investment in the new products needed to beat the challenges of rising drug resistance. Dr Bill Love, CEO of Destiny Pharma said “We welcome the publication of this Declaration, which demonstrates the need for a coordinated plan at a governmental level to tackle the issue of antibiotic resistance”.
